SCHEMBL2686172

SCHEMBL2686172

CC(C)(C)OC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)Nc1cnc(-c2ccncc2)s1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CTSS P25774 8/20 0.53
CTSK P43235 7/20 0.53
GPR142 Q7Z601 1/20 0.51
SCN9A Q15858 4/20 0.44
HDAC8 Q9BY41 1/20 0.44
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
PRKACA P17612 1/20 0.42
ROCK1 Q13464 1/20 0.42
USP30 Q70CQ3 1/20 0.42
PTPRB P23467 1/20 0.41
BCL2 P10415 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686171 1.00 CTSS (0.53) CTSSCTSKGPR142SCN9AHDAC8
SCHEMBL2686800 0.91 GPR142 (0.61) CTSSCTSKGPR142SCN9AHDAC8
SCHEMBL2686802 0.91 GPR142 (0.61) CTSSCTSKGPR142SCN9AHDAC8
SCHEMBL2686764 0.86 GPR142 (0.59) GPR142PRKACAROCK1USP30
SCHEMBL27744402 0.83 CTSS (0.59) CTSSCTSKSCN9AHDAC8CTSL
SCHEMBL27723748 0.83 CTSS (0.59) CTSSCTSKSCN9AHDAC8CTSL
SCHEMBL5960493 0.81 CTSS (0.55) CTSSCTSKGPR142SCN9AHDAC8
SCHEMBL2684844 0.78 GPR142 (0.55) GPR142PRKACAROCK1
SCHEMBL2684847 0.78 GPR142 (0.55) GPR142PRKACAROCK1
SCHEMBL2684752 0.78 CTSS (0.53) CTSSCTSKGPR142SCN9AHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A CTSS 3372/4885CTSK 3300/4885GPR142 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.